المنشورات طباعة Alva-Ruiz R, Watkins RD, Tomlinson JL, Yonkus JA, Abdelrahman AM, Conboy CB, Jessen E, Werneburg NW, Kuipers H, Sample JW, Gores GJ, Ilyas SI, Truty MJ, Smoot RL. YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS Open Bio. 2024 Nov; 14 (11):1873-1887 Epub 2024 Sept 19 View PubMed Nasser-Ghodsi N, Eaton JE, Smith BH, Venkatesh SK, Heimbach JK, Taner T, Welle CL, Ilyas SI, Gores GJ, Rosen CB. Transplantation Within 6 Months of Registration does not Enhance Survival for Patients with Perihilar Cholangiocarcinoma. Ann Surg. 2024 Jul 4 Epub 2024 July 04 View PubMed Yang Y, Wang J, Wan J, Cheng Q, Cheng Z, Zhou X, Wang O, Shi K, Wang L, Wang B, Zhu X, Chen J, Feng D, Liu Y, Jahan-Mihan Y, Haddock AN, Edenfield BH, Peng G, Hohenstein JD, McCabe CE, O'Brien DR, Wang C, Ilyas SI, Jiang L, Torbenson MS, Wang H, Nakhleh RE, Shi X, Wang Y, Bi Y, Gores GJ, Patel T, Ji B. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice. J Hepatol. 2024 Jul; 81 (1):120-134 Epub 2024 Feb 28 View PubMed Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Jul; 26 (7):938-948 Epub 2024 Apr 23 View PubMed Tomlinson JL, Li B, Yang J, Loeuillard E, Stumpf HE, Kuipers H, Watkins R, Carlson DM, Willhite J, O'Brien DR, Graham RP, Chen X, Smoot RL, Dong H, Gores GJ, Ilyas SI. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. J Hepatol. 2024 Jun; 80 (6):892-903 Epub 2024 Mar 07 View PubMed Jackson LE, Tomlinson JL, Alva-Ruiz R, Gregory LA, Byeon SK, Abdelrahman AM, Mun DG, Grant CW, Fogarty ZC, Wang C, Roberts LR, Graham RP, Borad MJ, Ilyas SI, Gores GJ, Pandey A, Athreya AP, Smoot RL. Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma. JHEP Rep. 2024 Jun; 6 (6):101068 Epub 2024 Mar 18 View PubMed Garcia Moreno AS, Guicciardi ME, Wixom AQ, Jessen E, Yang J, Ilyas SI, Bianchi JK, Pinto E Vairo F, Lazaridis KN, Gores GJ. IL-17 signaling in primary sclerosing cholangitis patient-derived organoids. Hepatol Commun. 2024 Jun 1; 8 (6) Epub 2024 June 03 View PubMed Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Apr 24 [Epub ahead of print] View PubMed Parthasarathy G, Mauer AS, Golla N, Daniel PV, Kim LH, Sidhu GS, Marek GW 3rd, Loeuillard E, Krishnan A, Lee HSK, Pavelko KD, Charlton M, Hirsova P, Ilyas SI, Malhi H. Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 8; 9 (3) Epub 2024 Feb 08 View PubMed Loeuillard EJ, Li B, Stumpf HE, Yang J, Willhite JR, Tomlinson JL, Rohakhtar FR, Simon VA, Graham RP, Smoot RL, Dong H, Ilyas SI. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2024; 17 (5):853-876 Epub 2024 Jan 14 View PubMed Tomlinson JL, Valle JW, Ilyas SI. Immunobiology of cholangiocarcinoma. J Hepatol. 2023 Sep; 79 (3):867-875 Epub 2023 May 16 View PubMed Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023 Jul; 20 (7):470-486 Epub 2023 May 15 View PubMed European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023 Jul; 79 (1):181-208 Epub 2023 Apr 20 View PubMed Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS Jr, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology. 2023 Jun 1; 77 (6):1943-1957 Epub 2022 Oct 11 View PubMed Bowlus CL, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology 2023 Jun 1; 77 (6):E176-E177 Epub 2023 Jan 26 View PubMed Forman LM, Sapisochin G, Assis DN, Arrive L, Bergquist A, Bowlus CL, Deneau M, Ilyas SI, Lunsford KE, Martinez M, Shroff R, Tabibian JH. Reply: Living donor liver transplantation for people with PSC. Hepatology 2023 May 1; 77 (5):E97-E98 Epub 2023 Jan 03 View PubMed Udompap P, Ramkissoon R, Povero D, Hernandez-Tejero M, Arab JP, Ilyas SI. Hepatology Highlights Hepatology. 2023; 705-706. Bowlus CL, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1; 77 (2):659-702 Epub 2022 Oct 20 View PubMed Conboy CB, Yonkus JA, Buckarma EH, Mun DG, Werneburg NW, Watkins RD, Alva-Ruiz R, Tomlinson JL, Guo Y, Wang J, O'Brien D, McCabe CE, Jessen E, Graham RP, Buijsman RC, Vu D, de Man J, Ilyas SI, Truty MJ, Borad M, Pandey A, Gores GJ, Smoot RL. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. J Hepatol. 2023 Jan; 78 (1):142-152 Epub 2022 Sept 24 View PubMed De la Garza-Ramos C, Montazeri SA, Musto KR, Kapp MD, Lewis AR, Frey G, Paz-Fumagalli R, Ilyas S, Harnois DM, Majeed U, Patel T, Toskich B. Outcomes of Radiation Segmentectomy for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease versus Chronic Viral Hepatitis. J Hepatocell Carcinoma. 2023; 10:987-996 Epub 2023 June 23 View PubMed Pery R, Smoot RL, Thiels CA, Cleary SP, Vierkant RA, Ilyas SI, Gores GJ, Nagorney DM. Hepatobiliary and pancreatic resection for cholangiocarcinoma in patients with primary sclerosing cholangitis. Br J Surg. 2022 Oct 14; 109 (11):1032-1035 View PubMed Wu T, Povero D, Parthasarathy G, Idalsoaga F, Arab JP, Ilyas SI. Hepatology highlights. Hepatology. 2022 Oct; 76 (4):901-902 View PubMed Penrice DD, Tomlinson J, Watkins R, Ayares G, Arab JP, Ilyas SI. Hepatology Highlights. Hepatology. 2022 Aug; 76 (2):287-288 View PubMed Povero D, Ahn JC, Arnold J, Udompap P, Ilyas SI, Arab JP. Hepatology Highlights. Hepatology. 2022 Jul; 76 (1):1-2 View PubMed Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology. 2022 Jun; 75 (6):1604-1626 Epub 2022 Apr 07 View PubMed Alva-Ruiz R, Wu T, Idalsoaga F, Ramkissoon R, Arab JP, Ilyas SI. Hepatology highlights. Hepatology. 2022 Jun; 75 (6):1363-1364 View PubMed Miyabe K, Chandrasekhara V, Wongjarupong N, Chen J, Yang L, Johnson S, Chia N, Walther-Antonio M, Yao JZ, Harrington SC, Nordyke CK, Eaton JE, Gossard AA, Oli S, Ali HA, Lavu S, Giama NH, Hassan FA, Ali HM, Enders FT, Ilyas SI, Gores GJ, Topazian MD, Kashyap PC, Roberts LR. Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers (Basel). 2022 Apr 24; 14 (9) View PubMed Tomlinson JL, Ahn JC, Povero D, Ramkissoon R, Ilyas SI, Arab JP. Hepatology Highlights. Hepatology. 2022 Apr; 75 (4):775-776 View PubMed Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K, Liu Q, Lou Z, Dong H, Sharpe AH, Shah VH, Kang N. PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-beta receptor I versus II. Cell Rep. 2022 Feb 8; 38 (6):110349 View PubMed Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets. 2021 Oct; 25 (10):835-845 Epub 2021 Dec 03 View PubMed Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat Rev Dis Primers. 2021 Sep 9; 7 (1):65 Epub 2021 Sept 09 View PubMed Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs. 2021 Apr; 30 (4):429-438 Epub 2020 Dec 28 View PubMed Ilyas SI, Wang J, El-Khoueiry AB. Liver Cancer Immunity. Hepatology. 2021 Jan; 73 Suppl 1 (Suppl 1):86-103 Epub 2020 Nov 07 View PubMed Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28 View PubMed Van Treeck BJ, Lotfalla M, Czeczok TW, Mounajjed T, Moreira RK, Allende DS, Reid MD, Naini BV, Westerhoff M, Adsay NV, Kerr SE, Rizvi SH, I Ilyas SH, Smoot RL, Liu Y, Davila J, Graham RP. Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver. Am J Clin Pathol. 2020 Nov 4; 154 (6):837-847 View PubMed Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O'Brien DR, Wang C, Ilyas SI, Smoot RL. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Mol Cancer Res. 2020 Oct; 18 (10):1574-1588 Epub 2020 July 09 View PubMed Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020 Oct 1; 130 (10):5380-5396 View PubMed Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020 Sep; 17 (9):557-588 Epub 2020 June 30 View PubMed Ilyas SI, Gores GJ. The Two Faces of Relaxin in Cancer: Antitumor or Protumor? Hepatology 2020 Mar; 71 (3):1117-1119 View PubMed Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019 Oct; 1 (4):297-311 Epub 2019 July 10 View PubMed Loeuillard E, Fischbach SR, Gores GJ, Ilyas SI. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 1865 (5):982-992 Epub 2018 Apr 05 View PubMed Ilyas SI, Gores GJ. Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. Hepatology 2018 Dec; 68 (6):2428-2430 Epub 2018 Nov 07 View PubMed Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Ilyas SI, Kaufmann SH, Gores GJ. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol. 2018 Jun; 68 (6):1228-1238 Epub 2018 Mar 09 View PubMed Ilyas SI, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis. 2018 May; 38 (2):160-169 Epub 2018 June 05 View PubMed Mertens JC, Ilyas SI, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018 Apr; 1864 (4 Pt B):1454-1460 Epub 2017 Aug 24 View PubMed Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb; 15 (2):95-111 Epub 2017 Oct 10 View PubMed Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget. 2018 Jan 19; 9 (5):5892-5905 Epub 2017 Dec 22 View PubMed Anderson B, Rizvi S, Lin G, Nehra V. A case of heart failure and diarrhoea. Gut. 2017 Oct; 66 (10):1778 Epub 2016 Nov 09 View PubMed Ilyas SI, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017 Sep; 67 (3):632-644 Epub 2017 Apr 05 View PubMed Rizvi S, Yang JD, Gores GJ. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 2017 Jan; 66 (1):4-5 Epub 2016 Sept 01 View PubMed Ilyas SI, Borad MJ. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol. 2016 Oct; 7 (5):789-796 View PubMed Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 Oct; 64 (4):1178-88 Epub 2016 Aug 24 View PubMed Ilyas SI, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, Zhang L, Trushina E, Truty MJ, Gores GJ. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016 Apr 8; 291 (15):8031-47 Epub 2016 Jan 29 View PubMed Ilyas SI, Gores GJ. Liver capsule: Cholangiocarcinoma (CCA). Hepatology. 2016 Apr; 63 (4):1356 Epub 2016 Feb 01 View PubMed Rizvi S, Yamada D, Hirsova P, Bronk S, Werneburg NW, Zhang L, Trushina E, Gores GJ. Mo1469 Fibroblast Growth Factor Receptor (FGFR) Signaling Activation Culminates in a Mcl-1 Regulated Tumor Survival Pathway in CC Gastroenterology. 2016; 150(4):S1124. Ilyas SI, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13 (12):2152-65 Epub 2015 June 05 View PubMed Yamada D, Ilyas SI, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015 May; 61 (5):1627-42 Epub 2015 Mar 20 View PubMed Rizvi S, Gores GJ. Molecular Profiling and Research of Therapeutic Targets. Dig Dis. 2015; 33 (4):586-9 Epub 2015 July 06 View PubMed Ilyas SI, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis. 2014 Nov; 34 (4):456-64 Epub 2014 Nov 04 View PubMed Ilyas SI, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem. 2014 Aug 15; 289 (33):22835-22849 Epub 2014 June 27 View PubMed Hartman DJ, Krasinskas AM, Uttam S, Staton K, Bista R, I Ilyas S, Rizvi S, Slivka A, Brand R, Liu Y. Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens. Am J Clin Pathol. 2014 Jun; 141 (6):884-91 View PubMed Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014; 32 (5):564-9 Epub 2014 July 14 View PubMed Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014; 89 (3):216-24 Epub 2014 May 22 View PubMed Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec; 145 (6):1215-29 Epub 2013 Oct 15 View PubMed Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013 Oct; 58(4):1362-74. Epub 2013 Aug 06. View PubMed Fasanella KE, Bista RK, Staton K, Rizvi S, Uttam S, Zhao C, Sepulveda A, Brand RE, McGrath K, Liu Y. Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect". J Cancer. 2013; 4: (8)626-34. View PubMed Lomberk G, Mathison AJ, Grzenda A, Seo S, DeMars CJ, Ilyas SI, Bonilla-Velez J, Calvo E, Fernandez-Zapico ME, Iovanna J, Buttar NS, Urrutia R. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J Biol Chem. 2012 Apr 13; 287 (16):13026-39 Epub 2012 Feb 08 View PubMed Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol. 2011 Nov; 106: (11)1872-9. View PubMed Ilyas SI, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberk G, Fernandez-Zapico ME, Buttar NS. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 2010 Sep 1; 70 (17):6787-96 Epub 2010 July 20 View PubMed Buttar NS, DeMars CJ, Lomberk G, Ilyas SI, Bonilla-Velez J, Achra S, Rashtak S, Wang KK, Fernandez-Zapico ME, Urrutia R. Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. J Biol Chem. 2010 Apr 9; 285 (15):11433-44 Epub 2010 Feb 12 View PubMed Ilyas S, DeMars CJ, Buttar NS. Chemoprevention in Barrett's esophagus. J Gastrointest Cancer. 2007; 38 (1):1-9 View PubMed PST-20258407 الصفحة الرئيسية المنشورات